Reactivation of latent cytomegalovirus infection in patients with rheumatologic disease: a case–control study
Tóm tắt
The disease burden, risk factors and clinical sequelae of CMV reactivation in patients with rheumatologic conditions is poorly understood. We have described a cohort with underlying rheumatic disease and CMV, and compared a subgroup with systemic lupus erythematosus (SLE) to controls to identify potential risk factors for CMV reactivation. Adults with rheumatic disease and CMV infection from 2000–2015 were identified. SLE cases were matched 3:1 with controls based on age, sex and year of admission, and compared. Fourteen patients were included (6 SLE, 4 rheumatoid arthritis, 2 sarcoidosis, 1 psoriatic arthritis, 1 microscopic polyangiitis). Seven had viremia alone, the remainder tissue-invasive disease. Thirteen received glucocorticoids prior to CMV reactivation. Fever was the most common symptom, and coinfections were seen in eight including four with bacteremia. Thirteen received antiviral therapy (median 33 days), four died during hospitalization. Six patients with underlying SLE and CMV reactivation were compared to 18 SLE controls. Cases received more glucocorticoids prior to admission (median 36.5 vs. 2.5 mg/day, p = 0.006), had longer hospitalizations (median 47 vs. 7 days, p = 0.006) and more coinfections (67% vs. 17%, p = 0.04). There were no significant differences in symptoms at presentation. CMV reactivation occurs in patients with rheumatologic disease, can result in severe clinical sequelae, and is difficult to distinguish from a flare of the underlying disease. Patients with CMV received higher doses of glucocorticoids and developed more co-infections. CMV should be considered during the evaluation of a febrile illness in this complex patient population.
Tài liệu tham khảo
Gandhi MK, Khanna R (2004) Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis 4(12):725–738. https://doi.org/10.1016/S1473-3099(04)01202-2
Griffiths P, Baraniak I, Reeves M (2015) The pathogenesis of human cytomegalovirus. J Pathol 235(2):288–297. https://doi.org/10.1002/path.4437
Kotton CN, Kumar D, Caliendo AM, Asberg A, Chou S, Danziger-Isakov L, Humar A, Transplantation Society International CMVCG (2013) Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 96(4):333–360. https://doi.org/10.1097/TP.0b013e31829df29d
Nogalski MT, Collins-McMillen D, Yurochko AD (2014) Overview of human cytomegalovirus pathogenesis. Methods Mol Biol 1119:15–28. https://doi.org/10.1007/978-1-62703-788-4_2
Ozaki T, Yamashita H, Kaneko S, Yorifuji H, Takahashi H, Ueda Y, Takahashi Y, Kaneko H, Kano T, Mimori A (2013) Cytomegalovirus disease of the upper gastrointestinal tract in patients with rheumatic diseases: a case series and literature review. Clin Rheumatol 32(11):1683–1690. https://doi.org/10.1007/s10067-013-2363-7
Takizawa Y, Inokuma S, Tanaka Y, Saito K, Atsumi T, Hirakata M, Kameda H, Hirohata S, Kondo H, Kumagai S, Tanaka Y (2008) Clinical characteristics of cytomegalovirus infection in rheumatic diseases: multicentre survey in a large patient population. Rheumatology (Oxford) 47(9):1373–1378. https://doi.org/10.1093/rheumatology/ken231
Zhang L, Tao J, Wen Y, Li L, Wu X, Li X, Li X (2017) Cytomegalovirus infection in patients with lupus nephritis: clinical and laboratory features and therapeutic considerations. Clin Exp Med. https://doi.org/10.1007/s10238-017-0456-3
Mori T, Kameda H, Ogawa H, Iizuka A, Sekiguchi N, Takei H, Nagasawa H, Tokuhira M, Tanaka T, Saito Y, Amano K, Abe T, Takeuchi T (2004) Incidence of cytomegalovirus reactivation in patients with inflammatory connective tissue diseases who are under immunosuppressive therapy. J Rheumatol 31(7):1349–1351
Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Fu B, Ustianowski AP, Watson KD, Lunt M, Symmons DP, Consortium BCC, British Society for Rheumatology Biologics R (2011) Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) 50(1):124–131. https://doi.org/10.1093/rheumatology/keq242
Tsai WP, Chen MH, Lee MH, Yu KH, Wu MW, Liou LB (2012) Cytomegalovirus infection causes morbidity and mortality in patients with autoimmune diseases, particularly systemic lupus: in a Chinese population in Taiwan. Rheumatol Int 32(9):2901–2908. https://doi.org/10.1007/s00296-011-2131-4
Berman N, Belmont HM (2017) Disseminated cytomegalovirus infection complicating active treatment of systemic lupus erythematosus: an emerging problem. Lupus 26(4):431–434. https://doi.org/10.1177/0961203316671817
Lee KY, Yoo BW, Ahn SS, Bae WH, Lee H, Jung SM, Lee SW, Park YB, Song JJ (2017) Predictors of mortality in autoimmune disease patients with concurrent cytomegalovirus infections detected by quantitative real-time PCR. PLoS ONE 12(7):e0181590. https://doi.org/10.1371/journal.pone.0181590
Choo HMC, Cher WQ, Kwan YH, Fong WWS (2019) Risk factors for cytomegalovirus disease in systemic lupus erythematosus (SLE): a systematic review. Adv Rheumatol 59(1):12. https://doi.org/10.1186/s42358-019-0055-y
Ramos-Casals M, Cuadrado MJ, Alba P, Sanna G, Brito-Zeron P, Bertolaccini L, Babini A, Moreno A, D'Cruz D, Khamashta MA (2008) Acute viral infections in patients with systemic lupus erythematosus: description of 23 cases and review of the literature. Medicine (Baltimore) 87(6):311–318. https://doi.org/10.1097/MD.0b013e31818ec711
Yoon KH, Fong KY, Tambyah PA (2002) Fatal cytomegalovirus infection in two patients with systemic lupus erythematosus undergoing intensive immunosuppressive therapy: role for cytomegalovirus vigilance and prophylaxis? J Clin Rheumatol 8(4):217–222
Sekigawa I, Nawata M, Seta N, Yamada M, Iida N, Hashimoto H (2002) Cytomegalovirus infection in patients with systemic lupus erythematosus. Clin Exp Rheumatol 20(4):559–564
Perez-Mercado AE, Vila-Perez S (2010) Cytomegalovirus as a trigger for systemic lupus erythematosus. J Clin Rheumatol 16(7):335–337. https://doi.org/10.1097/RHU.0b013e3181f4cf52
Lim CC, Tung YT, Tan BH, Lee PH, Mok IY, Oon L, Chan KP, Choo JC (2017) Epidemiology and risk factors for cytomegalovirus infection in glomerular diseases treated with immunosuppressive therapy. Nephrology (Carlton) 23(7):676–681. https://doi.org/10.1111/nep.13071
Mencarini J, Spinicci M, Bartalesi F (2016) Risk of cytomegalovirus reactivation in patients with immune-mediated inflammatory diseases undergoing biologic treatment: a real matter? Reumatismo 68(3):144–147. https://doi.org/10.4081/reumatismo.2016.897
Xue Y, Jiang L, Wan WG, Chen YM, Zhang J, Zhang ZC (2016) Cytomegalovirus pneumonia in patients with rheumatic diseases after immunosuppressive therapy: a single center study in China. Chin Med J (Engl) 129(3):267–273. https://doi.org/10.4103/0366-6999.174490
Buttgereit F, da Silva JA, Boers M, Burmester GR, Cutolo M, Jacobs J, Kirwan J, Kohler L, Van Riel P, Vischer T, Bijlsma JW (2002) Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis 61(8):718–722
Medicode Ingenix (1998) ICD-9-CM : International classification of diseases, 9th revision, clinical modification. Physician ICD-9-CM, 5th edn. Medicode, Salt Lake City
Genentech (2015) Valcyte (valganciclovir), package insert. Genentech, San Francisco, California, USA
Genentech (2016) Cytovene (ganciclovir), package insert. Genentech, San Francisco, California, USA
Ikeda K, Nakajima S, Tanji K, Hirai T, Uomori K, Morimoto S, Tomita S, Fukunaga M, Tamura N, Sekigawa I (2017) Intestinal perforation due to hemorrhagic cytomegalovirus enteritis in a patient with severe uncontrolled lupus nephritis: a case and review of the literature. Rheumatol Int 37(8):1395–1399. https://doi.org/10.1007/s00296-017-3693-6
Hanley PJ, Bollard CM (2014) Controlling cytomegalovirus: helping the immune system take the lead. Viruses 6(6):2242–2258. https://doi.org/10.3390/v6062242